Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

Smith & Nephew Plc delivers strong H1 with profit up 31%

Smith+Nephew reported 5.0% underlying revenue growth and a 30.6% rise in operating profit for H1 2025. EPS rose 36.6% to 33.5¢ and free cash flow surged to $244m. The company..

August 5, 2025

Aptamer Group reports 41% revenue growth and new licensing deals

Aptamer Group posted unaudited revenue of £1.20 million for the year ended 30 June 2025, up 41% from the previous year. The company secured two new royalty agreements and advanced..

July 31, 2025

GSK raises 2025 guidance after strong Q2 performance

GSK reported Q2 2025 turnover of £8.0bn, up 6% CER, with strong growth in Specialty Medicines (+15%) and Vaccines (+9%). Core EPS rose 15% to 46.5p...

July 30, 2025

One Health Group a “buy” in This is Money Midas Share Tips

Analysts at Midas Share Tips described the company as well-managed and well-positioned to benefit from ongoing NHS reliance on external capacity...

July 29, 2025

GSK and Hengrui Pharma to develop up to 12 new medicine programmes

GSK plc has entered agreements with Hengrui Pharma to develop up to 12 innovative medicines, including an exclusive worldwide licence (ex‑China) for HRS‑9821, a potential best‑in‑class PDE3/4 inhibitor for COPD,..

July 28, 2025

When buildings become health’s best asset

Investors are discovering that medical properties offer a unique blend of resilience and growth potential in unpredictable markets...

July 23, 2025

One Health Group PLC closely aligned with government 10-year Health Plan

As the National Health Service (NHS) navigates unprecedented pressures, collaboration with independent providers remains vital to ensuring patients receive timely and appropriate care. This partnership between the NHS and the independent sector..

July 22, 2025

AstraZeneca to invest $50bn in the US, new Virginia manufacturing site planned

AstraZeneca will invest $50bn in the United States by 2030, including a multi‑billion dollar drug substance facility in Virginia for its weight management and metabolic portfolio...

July 22, 2025

Oxford Nanopore delivers 25% revenue growth in H1 2025

Revenue rose to £105 million, up 28% constant currency, driven by PromethION growth of 59% and strong gains in Applied markets. Adjusted EBITDA loss narrowed, cash stood at £337 million..

July 21, 2025

Aptamer Group extends Unilever collaboration for deodorant Optimers

Aptamer Group has secured additional paid work from Unilever under their existing collaboration, advancing Optimers as deodorant actives with expanded stability testing ahead of on‑person trials...

July 21, 2025

GSK’s Arexvy FDA review accepted for adults 18-49 at increased risk

The US FDA has accepted GSK’s application to extend Arexvy to adults aged 18-49 at increased risk of severe RSV infection, supported by positive Phase IIIb data; a decision is..

July 14, 2025

AstraZeneca’s Baxdrostat meets Phase III endpoints in Hypertension trial

AstraZeneca reports that baxdrostat at 1mg and 2mg doses significantly reduced mean seated systolic blood pressure at 12 weeks versus placebo in patients with uncontrolled or treatment-resistant hypertension, meeting all..

July 14, 2025

Aptamer Group raises £2.0 million in share placing

Aptamer has raised £2.0 million (before expenses) by placing 666,666,666 new ordinary shares at 0.3 p each, representing 25.1 per cent of its enlarged issued share capital. The proceeds will..

July 7, 2025

One Health Group granted planning approval for Scunthorpe surgical hub

One Health Group plc has secured planning permission for its first surgical hub in Scunthorpe, Lincolnshire, set to open in late summer 2026...

July 4, 2025

AstraZeneca’s Imfinzi approved in EU for muscle-invasive bladder cancer

AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU for use alongside chemotherapy before, and as monotherapy after, bladder removal surgery in adults with resectable muscle-invasive bladder cancer...

July 4, 2025

Aptamer Group raises £2m to fund growth

Aptamer Group plc has raised £2.0 million (before expenses) via a placing of new ordinary shares at 0.3p per share, representing a 21.1% discount...

July 4, 2025

One Health Group: Record Growth and New Surgical Hub Development (LON:OHGR)

One Health Group CEO Adam Binns discusses the company’s record growth and strategic future, highlighting a 28% increase in NHS patient referrals, the successful AIM listing raising £7.8 million, and..

July 2, 2025

NIOX Group a ‘Buy’ with Dependable Growth and Cashflow, Singer (LON: NIOX)

NIOX continues to capitalise on both clinical and research markets, delivering consistent growth and strengthening its cash position...

July 1, 2025

One Health reshaping surgical care across northern England

One Health Group is steadily extending NHS‑backed elective care in northern England, underpinned by a 23% revenue surge and a funded surgical hub...

July 1, 2025

Aptamer advances liver fibrosis therapy with targeted gene delivery

Aptamer Group has identified a novel target using its Optimer® platform to deliver gene therapy directly to liver scarring cells...

June 30, 2025

News and Interview Alerts

Company Presentations

PetroNeft Resources Investor Presentation

Dekel Agri-Vision Investor Presentation 2021

Valeura Energy Corporate Overview 2021

Premier Miton Diverse Income Trust plc Investor Presentation

Q&As

Hardman & Co

ICG Enterprise Trust FY’26 results: look to future realisations

11 June 2026

NB Private Equity Partners 2025 results: Looking to future realisations

29 May 2026

Chesnara Plc: Showing good operational progress

17 April 2026

Arbuthnot Banking Group Plc: 2025 lower margins, 2026 profit stability

1 April 2026

Green News

Quadrise reports progress on Valkor pilot deployment in Utah

12 June 2026

Thor Energy reports elevated hydrogen results at HY-Range project

9 June 2026

Drax agrees £548m cash acquisition of Bluefield Solar Income Fund

1 June 2026

Drax completes commissioning of Hirwaun Power Station

29 May 2026

View all Sustainable sectors, Plcs and news >>

Search

Latest Interviews

BrokerTalk

Sintana Energy Initiated at Buy with 62p Target Price, Cavendish Highlights “Walking amongst giants” Opportunity

17 February 2026

Geiger Counter positioning for a sustained uranium rally | Latest Research

16 February 2026

Manx Financial Group Builds Strong Momentum Heading into 2026 – Shore Capital

16 February 2026

Vp plc Earnings Reset Reflects Market Headwinds, Says Equity Development

13 February 2026

Valeura Delivers Strong Reserve Growth and Upside Potential, Says Auctus Advisors

12 February 2026

Funds

Agricultural commodities look mispriced as fertiliser risk builds | Ruffer Investment Company

15 June 2026

Diverse Income Trust: UK equity outlook and reconstruction proposal (LON:DIVI)

11 June 2026

Biotech Growth Trust reports strong one-year performance

11 June 2026

Ruffer Investment Company delivers positive year-to-date gains

11 June 2026

Finsbury Growth & Income Trust highlights portfolio value in May

9 June 2026

View all Funds, Market Insights and news >>

FTSE 100 News

Imperial Brands maintains FY26 guidance after mixed first half

12 May 2026

IMI reconfirms 2026 guidance after strong first-quarter organic growth

12 May 2026

Vodafone FY26 results: Service revenue up 8.8%, Germany returns to growth

12 May 2026

FTSE 100 edges higher as selective gains support a cautious market

11 May 2026

UK Broker Ratings

Goodwin PLC (GDWN.L) Stock Analysis: A Hidden Gem in Specialty Industrial Machinery with Robust Revenue Growth

9 June 2026

FirstGroup PLC (FGP.L) Stock Analysis: Examining a Potential 50% Upside for Investors

9 June 2026

Chemring Group PLC (CHG.L) Stock Analysis: Aerospace & Defense Player with a 22% Upside Potential

9 June 2026

Hilton Food Group PLC (HFG.L) Stock Analysis: Uncovering a 34.97% Potential Upside in the Packaged Foods Sector

9 June 2026

ABERDEEN GROUP PLC (ABDN.L) Stock Analysis: Navigating the Investment Landscape with a 6.12% Dividend Yield

9 June 2026

Health

Smith & Nephew Plc delivers strong H1 with profit up 31%

Smith+Nephew reported 5.0% underlying revenue growth and a 30.6% rise in operating profit for H1 2025. EPS rose 36.6% to 33.5¢ and free cash flow surged to $244m. The company also announced a $500m share buyback for H2, supported by strong cash generation and margin expansion...

August 5, 2025

Aptamer Group reports 41% revenue growth and new licensing deals

Aptamer Group posted unaudited revenue of £1.20 million for the year ended 30 June 2025, up 41% from the previous year. The company secured two new royalty agreements and advanced multiple licensing discussions, supported by a strengthened cash position following a £1.83 million fundraise...

July 31, 2025

GSK raises 2025 guidance after strong Q2 performance

GSK reported Q2 2025 turnover of £8.0bn, up 6% CER, with strong growth in Specialty Medicines (+15%) and Vaccines (+9%). Core EPS rose 15% to 46.5p...

July 30, 2025

One Health Group a “buy” in This is Money Midas Share Tips

Analysts at Midas Share Tips described the company as well-managed and well-positioned to benefit from ongoing NHS reliance on external capacity...

July 29, 2025

GSK and Hengrui Pharma to develop up to 12 new medicine programmes

July 28, 2025

When buildings become health’s best asset

Investors are discovering that medical properties offer a unique blend of resilience and growth potential in unpredictable markets...

July 23, 2025

One Health Group PLC closely aligned with government 10-year Health Plan

July 22, 2025

AstraZeneca to invest $50bn in the US, new Virginia manufacturing site planned

AstraZeneca will invest $50bn in the United States by 2030, including a multi‑billion dollar drug substance facility in Virginia for its weight management and metabolic portfolio...

July 22, 2025

Oxford Nanopore delivers 25% revenue growth in H1 2025

Revenue rose to £105 million, up 28% constant currency, driven by PromethION growth of 59% and strong gains in Applied markets. Adjusted EBITDA loss narrowed, cash stood at £337 million and full‑year guidance remains on track...

July 21, 2025

Aptamer Group extends Unilever collaboration for deodorant Optimers

Aptamer Group has secured additional paid work from Unilever under their existing collaboration, advancing Optimers as deodorant actives with expanded stability testing ahead of on‑person trials...

July 21, 2025

GSK’s Arexvy FDA review accepted for adults 18-49 at increased risk

The US FDA has accepted GSK’s application to extend Arexvy to adults aged 18-49 at increased risk of severe RSV infection, supported by positive Phase IIIb data; a decision is expected in H1 2026...

July 14, 2025

AstraZeneca’s Baxdrostat meets Phase III endpoints in Hypertension trial

July 14, 2025

Aptamer Group raises £2.0 million in share placing

Aptamer has raised £2.0 million (before expenses) by placing 666,666,666 new ordinary shares at 0.3 p each, representing 25.1 per cent of its enlarged issued share capital. The proceeds will accelerate commercialisation of the Optimer® platform, support in-house manufacturing, launch new biomarker services and develop AI-driven aptamer discovery...